Skip to main content

Table 5 Stratification of Best response based on type of Immunotherapy (PR = Partial Response, CR = Complete Response, SD = Stable Disease, PD = Progressive Disease, ORR = Objective Response Rate, DCR = Disease Control Rate)

From: Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma

Anti-PD-1 No Metformin N = 20 (60.6%) Metformin N = 14 (63.6%)  
Best Response
 PR 8 (40%) 7 (50%) P = 0.6
 CR 3 (15%) 3 (21.4%)
 SD 2 (10%) 2 (14.3%)
 PD 7 (35%) 2 (14.3%)
ORR 55% 71.4% P = 0.33
DCR 65% 85.7% P = 0.17
Median time to achieve best response (Months) 2.8 2.8 P = 0.28
Ipilimumab/Nivolumab No Metformin N = 9 (27.3%) Metformin N = 6 (27.3%)  
Best Response
 PR 6 (66.7%) 1 (16.7) P = 0.16
 CR 1 (11.1%) 2 (33.3%)
 SD 0 (0%) 0 (0%)
 PD 2 (22.2%) 3 (50%)
ORR 77.7% 50% P = 0.26
DCR 77.7% 50% P = 0.26
Median time to achieve best response (Months) 2.5 2.8 P = 0.9